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Introduction 
This SAP will be used as a working description within a Ph.D. project investigating the effectiveness of 
interdisciplinary non-pharmacological rehabilitation of patients with glioma. The trial is registered at 
www.ClinicalTrial.gov under the identifier NCT02221986 and The Regional Ethics Committee of Southern Denmark 
approved the study under j. nr.: S-20140108. 
Synopsis 
Gliomas, also known as World Health Organization (WHO) grade I-IV brain tumours1, are among the most devastating 
cancer diseases affecting humans. Poor prognosis, adverse effects from anticancer treatments and significant functional, 
emotional, and cognitive deficits affect the majority of patients, leaving them with impaired quality of life (QOL) and 
with a profound need for rehabilitation2. But according to a systematic literature review, rehabilitation in patients with 
brain tumours are rare3. This highlights the need to conduct research that investigates the effectiveness of non-
pharmacological rehabilitation among patients affected by glioma in robust methodological designs.  
Aim	&	study	hypothesis 
This randomized controlled clinical trial aims at investigating the effectiveness of standardized interdisciplinary non-
pharmacological rehabilitation of patients with gliomas during anticancer treatments. The study tests the hypothesis that 
patients attending a rehabilitation intervention of physical therapy and occupational therapy during chemo-radiation will 
report improvement in ‘overall QOL’ superior to patients attending standard rehabilitation regimens. 
A feasibility study and a protocol paper describing the design, methods, and outcomes have been published4,5.  
Study	design	
This study was designed as a parallel-arm randomized controlled clinical trial with patients allocated to an intervention-, 
or control group. 
Study	intervention 
Patients allocated to the intervention received a rehabilitation intervention of six weeks physical therapy, and depending 
on needs, tailored occupational therapy. The intervention was initiated simultaneously with the establishment of chemo-
radiation treatments, and all interventions occurred in continuance of the irradiation treatments at the Odense University 
Hospital (OUH), Denmark.  
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A case-report (under assessment) and a practice analysis6 describing the rational of the intervention modalities have 
been published. 
Controls	
The control group received ‘standard rehabilitation’, which in this study is defined as the level of rehabilitation patients 
attend after discharge from Odense University Hospital (OUH). At discharge from the Neurosurgical department 
patients will have an evaluation of their need for rehabilitation, as per instruction from the Danish Health Authority7. 
This evaluation may advise: no rehabilitation acquired, rehabilitation established by the municipality, or as specialized 
neurorehabilitation at OUH. 
Study	objectives	and	outcomes 
All outcomes were assessed at study entry (T1), at the completion of the intervention (T2), at a three-month follow-up 
(T3), and at a six-month follow-up (T4). This SAP deals with analyses that investigate the acute effects from T1 to T2 
(Figure 1). 
Figure 1 Study overview 
 
Purpose  
The purpose was to compare changes from T1 to T2 between the intervention- and the control group in ‘overall QOL’. 
The primary pre-specified outcome was the ‘Global health Status/QOL’ (GHS/QOL) scale from the European 
Organization for Research and Treatment of Cancer questionnaire (EORTC-QLQ-30). We hypothesize that patients 
attending the interdisciplinary rehabilitation (intervention) during chemo-radiation treatment will report improvements 
superior to patients having standard rehabilitation (control). 
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Primary	Outcome	
	
The GHS/QOL uses two unweighted responses to summarize a global score that measures ‘overall QOL’. Patients’ 
were asked to respond to the following questions: ‘How would you rate your overall health during the past week?’ and 
‘How would you rate your overall quality of life during the past week?’ Each item is scored on a scale ranging from 1 
[very poor] to 7 [excellent]. According to methods described in the 3rd edition of the EORTC-QLQ-C30 Scoring 
Manual, a linear transformation [GHS/QOL: S = ((RS −1) range)×100] was used to standardize raw scores to a numeric 
value ranging from 0 to 100, where a higher score represents a higher/better level of ‘overall QOL’8. ‘Overall QOL’ 
was chosen as a relevant outcome as the intervention is expected to have little impact on a clinical outcome of survival 
time9. Global health rating scales are the simplest way to measure QOL and frequently used in clinical research. They 
are easy to understand, allow expression of the disparate values and preferences of individual patients10, and they gives 
a concise way of summarizing the diverse components of health11. This study is the first to assess the effectiveness of 
non-pharmacologic rehabilitation in a randomized trial and we found no support in the literature to select a health-
related quality of life (HRQOL) domain over another, in respect to where an effect from the rehabilitation would be 
evident.  
Exploratory	objectives	and	outcomes 
The examination of exploratory secondary outcomes of HRQOL domains and symptoms, and functional performances 
allows for clinical indebt interpretation. They will only be supportive, explanatory and/or hypothesis generating which 
is why multiplicity is not considered a problem12 (Table 1). 
 
Table 1. Exploratory secondary outcomes 
Patient reported outcomes  
EORTC-QLQ-30 All domains beside GHS/QOL, and all single items 
EORTC-QLQ-BN20 All domains and single items 
Functional performance measures  
The Åstrand / Rhyming ergometer test Cardiovascular function 
A 3-8 repetition maximum tests of main extremity 
muscle synergies (kg) 
Dynamic muscle strength 
10-meter walk test Gait function 
SWAY measurements of postural control performed 
(cm2) 
Postural sway 
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Sample	size		
	
This study is the first to investigate the effectiveness of standardized rehabilitation of patients with glioma in a 
randomized design. Therefore, information regarding SD and expected effect from previous studies is unavailable. The 
sample-size is consequently based on a pre-trial with a limited sample of 24 patients. According to a review of the 
literature, a minimal clinically important difference of 10 points in ‘GHS/QOL’ scale has been suggested13. The trial 
was designed as a superiority trial, in the sense that we expect patients allocated to the intervention arm to improve at 
least 10 points or more than patients allocated to the standard rehabilitation arm, in the primary outcome of GHS/QOL 
from baseline to follow-up. To detect a 10-point difference in GHS/QOL between arms, with SD based on results from 
a feasibility study (n=24), a one-tailed sample size was calculated. At an expected ‘effect size’ of 10 points (0.407) with 
SD ± 24.6 increase in ‘GHS/QOL’ with a statistical power of β 0.8 and α of 0.05, the study requires 76 participants in 
each arm. To meet an expected dropout rate of approximately 15%, we will try to include 88 participants in each group. 
Settings,	recruitment	and	study	population 
Odense University Hospital is one of four national hospitals to perform surgery and medical treatment of patients with 
glioma, and the only hospital within the Region of Southern Denmark. Approximately 90 patients with primary glioma 
undergo surgical resection annually. All patients in this trial are recruited from the Neurosurgical department whereas 
the interventions and assessments were conducted in specially designed facilities at the Rehabilitation- and Neurology 
department.  
Recruitment 
Patients eligible for entering the study had to comply with all inclusion criteria listed in table 2  
Table 2. Eligibility criteria 
Inclusion criteria Exclusion criteria 
Confirmed diagnosis of glioma (WHO I-IV) 
Age ≥18 
Attending treatment at OUH 
Ability to communicate in Danish 
 
 
Karnofsky Performance Status ≥70 
Pregnancy  
Psychiatric diagnosis (such as uncontrolled schizophrenia, 
actively suicidal/self-harm or physically aggressive (based 
on clinical judgment)) 
Heart problems (New York Heart Association group III 
and IV) 
Severe impressive or expressive aphasia 
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Randomization	and	blinding  
The randomization sequence was created using Statistical Package for the Social Sciences (SPSS) version 21 Windows, 
and stratified by tumour classification (WHO grade II) / (WHO grade III+IV) with a 1:1 allocation. Random blocks 
varying in size from 8-10 was prepared in continuous numbered, opaque and sealed envelopes by a staff-member 
otherwise uninvolved in the conduction of the study. Immediate after baseline assessments, the allocation was reviled to 
the patient but kept hidden for the outcome assessor. In contrast to pharmacological interventions, it was not possible to 
blind patients to whether they received the rehabilitation interventions or not.  
 
Implementing	the	SAP 
A statistician will supervise all analyses.   
The following procedure will be used.  
• A database for the purpose of this study is established in collaboration between Odense Patient data 
Explorative Network (OPEN) and the principal researcher. This model will be approved by the academic 
seniority. 
• A data manager will code each treatment arm into a ´group treatment A´ and ´group treatment B´.  
• Blinded data will be handed to the primary author and a statistician, which will conduct the analyses.  
• Blinded results will be presented to the authors of the manuscript (as listed on the front page). Two consensus 
statements will be made prior to ‘unblinding’ the group allocation. One assuming that A is the intervention 
group, and one assuming that A is the control group.  
Statistical	analyses 
We will use descriptive statistics to describe group characteristics. 
Primary	outcome 
To test the study hypothesis that patients allocated to the intervention will experience effects in ‘overall QOL’ superior 
to patient in the standard rehabilitation group, and to predict an ‘overall QOL score at follow-up’, a multiple linear 
regression will be calculated based on group-allocation, gender, tumour grade and baseline values of GHS/QOL. 
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GHS/QOL residuals after regression on covariates (group allocation, gender, tumour grade, and baseline values of 
GHS/QOL) will be checked for normality by visual inspection using a Q-Q plot. Variance homogeneity will be 
inspected from plots of residuals against predicted outcome. 
Superiority is investigated using 95% confidence interval (CI) of the mean change in GHS/QOL between the two arms. 
The intervention is considered superior to standard rehabilitation regimens when the lower of the 95% CI excludes the 
superiority margin. 
All analyses are made by the complete case analyse principle, which should not produce any biases, as missing data are 
considered to be missing completely at random14, as according to the EORTC-QLQ-30 scoring manual8. Further, as 
only few observations are expected to be missing only a minimal harm will be done15.  
For sensitivity, a baseline value comparison of completers and non-completers will be conducted.      
For exploratory purposes, per-protocol (PP) analysis including patients only with high adherence and compliance will 
be conducted. This means that patients not fully committed to the criteria are excluded from the analysis. 
Adherence is defined by the number of sessions attended at the physical therapist supervised intervention. Adherence 
was dichotomized and considered high if the patient attended 10 or more session (>60%), and low if the patient 
attended nine or fewer sessions (<60%). 
Compliance is defined as the exercises performed by the patients at each physical therapist supervised session. 
Compliance was dichotomized and considered high if the patient completed six or more exercise from a possible seven 
exercises, as a mean, and low if the patient completed five or fewer exercises at the attended session. 
Exploratory	secondary	outcomes	
	
All secondary outcomes will be handled similar to the primary outcomes.  
Major	Protocol	Deviations 
In this SAP a corrected power calculation was conducted, due to application of wrong methods in the study protocol4. 
However, as we use the same data material to conduct the corrected calculation, and because the estimates are based on 
a limited sample, it is mealy to be considered as a rough estimate.  
Due to experiences gained from active patient recruitment, minor protocol deviations were made in the recruiting of 
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patients. However, this should have no influence on the scientific conclusion of the study.  
Originally we considered imputing missing values under consideration of generalized estimating equations or linear 
mixed models. However, we will follow instructions from a statistician and abstain from imputing data. 
Table	and	figure	legends	and	explanations	
 
Table 1 Exploratory secondary outcome 
Table 2 Eligibility criteria 
Table 3 Baseline demographics for patients with primary glioma allocated to the intervention-, versus the standard 
rehabilitation group. 
Table 4 GHS/QOL at T1 and T2 of the intervention-, versus control among patients primary glioma. Data are derived 
from multiple linear regressions and adjusted for group-allocation, gender, tumour grade, and baseline GHS/QOL 
scores. The table illustrates the results from the complete case population. 
Table 5 
Exploratory outcomes of EORTC-QLQ-30, BN-20, and functional performance measures. 
Figure 1 Study overview 
Figure 2 Flow of participants throughout the study  
______________________________________________________________________________________________ 
Table 1  
Patient reported outcomes  
EORTC-QLQ-30 All domains beside GHS/QOL, and all single items 
EORTC-QLQ-BN20 All domains and single items 
Functional performance measures  
The Åstrand / Rhyming ergometer test Cardiovascular function 
A 3-8 repetition maximum tests of main extremity 
muscle synergies (kg) 
Dynamic muscle strength 
10-meter walk test Gait function 
SWAY measurements of postural control performed 
(cm2) 
Postural sway 
 
Table 2:  
Inclusion criteria Exclusion criteria 
Confirmed diagnosis of glioma (WHO I-IV) 
Age ≥18 
Attending treatment at OUH 
Ability to communicate in Danish 
 
 
Karnofsky Performance Status ≥70 
Pregnancy  
Psychiatric diagnosis (such as uncontrolled schizophrenia, 
actively suicidal/self-harm or physically aggressive (based 
on clinical judgment)) 
Heart problems (New York Heart Association group III 
and IV) 
Severe impressive or expressive aphasia 
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Table 3  
Variable Intervention group (n=x) Control group (n=x) 
Age, years     
   Median (range)   
Gender (male (%))   
Body Mass Index (kg/m2)  
   Mean (SD)   
Married, cohabiting, or in a relationship (n= (%))   
Completed secondary school or higher (n= (%))   
   Primary School   
   Vocational education   
   Secondary school   
   Short-term 3rd level education   
   Medium length 3rd level education   
   Long-term 3rd level education   
   Other   
Employment status (n= (%))   
   Student   
   Unemployed, working at part-time or full-time   
   Early retirement or retired due to age   
   Other   
Karnofsky performance status (n= (%))   
   100    
   90   
   80   
   70   
Time from surgery to study entry, days   
   Median (range)    
WHO grade (n= (%))   
   II   
   III   
   IV   
Hemisphere (n= (%))   
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   Right   
   Left   
   Both   
Post resection residual tumour (n= (%))   
   Total removal1   
   Partial removal2   
   Decompression3   
Eloquent tumour location (n= (%))   
   Yes (n= (%))   
Medical treatment modalities   
   Surgery, radiation therapy and chemotherapy (n= (%))   
   Surgery and chemotherapy (n= (%))   
   Surgery and radiation therapy (n= (%))   
   Other (n= (%))    
Corticosteroid therapy (n= (%))   
   Yes (n= (%))   
Antiepileptic drug use (n= (%))   
   Yes (n= (%))   
AMPS, Mean (SD)   
   Motor   
   Process   
Rehabilitation at discharge from the hospital   
   No rehabilitation (n= (%))   
   Municipality services (n= (%))   
   Specialized neurorehabilitation at the hospital (n= (%))   
   
 
1All preoperatively imaged visually suspected tumour tissue is expected to be removed 
2More than 50% of the original tumour volume is expected to be removed 
3Less than 50% of the original tumour volume is expected to be removed   
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Table 4  
Primary outcome 
 
Intervention 
group predicted 
Control group 
predicted 
Coefficient p-value (95%CI) Adjusted R2 * 
GHS/QOL 
Scale (0-100) 
 
 
 
 
 
 
  
  
 
*Adjusted for gender, group-allocation, tumour-grade, and baseline GHS/QOL values.   
 
Table 5  
 
Exploratory outcome  Intervention 
group 
predicted 
Control 
group 
predicted 
Coefficient p-value 95% CI 
EORTC-QLQ-30      
Physical functioning      
Role functioning      
Emotional functioning      
Cognitive functioning      
Social functioning      
Fatigue      
Nausea and vomiting      
Pain      
Dyspnoea      
Insomnia      
Appetite loss      
Constipation      
Diarrhoea      
Financial difficulties      
      
BN-20 (symptoms) 
Future uncertainty      
Visual disorder      
Motor dysfunction      
Communication deficit      
Headaches      
Seizures      
Drowsiness      
Itchy skin      
Hair loss      
Weakness of legs      
Bladder control      
      
Functional performance 
Aerobe power      
1RM Leg press      
1RM Knee extension      
1RM Knee flexion      
1RM Elbow extension      
1 RM Elbow flexion      
Ten meter walking test 
(m/s) 
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Postural SWAY 
95%(cm2) 
     
Adjusted for gender, group-allocation, tumour-grade, and baseline GHS/QOL values.   
 
Figure 1 Study overview 
 
Outcomes were assessed at baseline (T1), at the end of the six-week intervention (T2), at a 12 week FU (T3), and 
questionnaires were sent at 6 month FU (T4) 
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Figure 2 Flowchart 
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